Yahoo! Finance: Dialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216
Robert Hromas, MD, FACP, dean of the Joe R. and Teresa Lazano Long School of Medicine, is mentioned in this Yahoo! Finance story about Dialectic Therapeutics, Inc., a Dallas-based biotechnology company focused on creating innovative new technologies to treat cancer. Dialectic has research partners and facilities at UT Health San Antonio and University of Florida Health.